{"id":82945,"date":"2026-06-24T16:41:23","date_gmt":"2026-06-24T14:41:23","guid":{"rendered":"https:\/\/cri1149.fr\/publication\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\/"},"modified":"2026-06-24T16:41:23","modified_gmt":"2026-06-24T14:41:23","slug":"vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab","status":"publish","type":"publication","link":"https:\/\/cri1149.fr\/en\/publication\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\/","title":{"rendered":"Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab\u2013bevacizumab"},"content":{"rendered":"\n<p>In this French\u2013Italian cohort, the VETC phenotype was predictive of improved outcomes in patients treated with atezolizumab\u2013bevacizumab, with longer survival than patients treated with durvalumab-tremelimumab.<br><br>Our findings suggest that VETC represent a promising biomarker for treatment stratification in advanced HCC. Prospective validation studies are now needed to determine whether VETC status could help guide the choice between systemic therapies in routine clinical practice.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"447\" src=\"https:\/\/cri1149.fr\/wp-content\/uploads\/2026\/06\/1781271821867-1024x447.jpg\" alt=\"\" class=\"wp-image-82944\" srcset=\"https:\/\/cri1149.fr\/wp-content\/uploads\/2026\/06\/1781271821867-1024x447.jpg 1024w, https:\/\/cri1149.fr\/wp-content\/uploads\/2026\/06\/1781271821867-300x131.jpg 300w, https:\/\/cri1149.fr\/wp-content\/uploads\/2026\/06\/1781271821867-768x335.jpg 768w, https:\/\/cri1149.fr\/wp-content\/uploads\/2026\/06\/1781271821867-1536x670.jpg 1536w, https:\/\/cri1149.fr\/wp-content\/uploads\/2026\/06\/1781271821867-1320x576.jpg 1320w, https:\/\/cri1149.fr\/wp-content\/uploads\/2026\/06\/1781271821867.jpg 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"sectitle0010\">Background &amp; Aims<\/h3>\n\n\n\n<p>Atezolizumab + bevacizumab and durvalumab + tremelimumab are the standard first-line therapies for advanced hepatocellular carcinoma (HCC). Histological variables routinely associated with outcomes remain poorly described. We aimed to assess the prognostic and predictive value of the vessels encapsulating tumor clusters (VETC) phenotype in this setting.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"sectitle0015\">Methods<\/h3>\n\n\n\n<p>We retrospectively analyzed 208 patients in a discovery cohort with advanced HCC treated with atezolizumab + bevacizumab and available pre-treatment biopsies, and 163 patients in a validation cohort, including 99 treated with atezolizumab + bevacizumab and 64 with durvalumab + tremelimumab. In addition to baseline clinico-biological variables, we assessed histological features, including the VETC phenotype, defined as complete (\u226555% of tumor area), or incomplete (1\u201354% of tumor area). Prognostic impacts were evaluated using multivariable Cox models.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"sectitle0020\">Results<\/h3>\n\n\n\n<p>In the discovery cohort, the complete VETC phenotype (n = 32) displayed the highest objective response rate in the cohort (66%&nbsp;<em>vs<\/em>. 37% in non- or incomplete VETC-HCC,&nbsp;<em>p<\/em>&nbsp;= 0.002), according to the modified RECIST. The complete VETC phenotype was independently associated with better progression-free survival (PFS) (hazard ratio [HR] 0.42, 95% CI 0.26\u20130.69,&nbsp;<em>p<\/em>&nbsp;&lt;0.001) and overall survival (OS) (HR 0.46, 95% CI 0.26\u20130.82,&nbsp;<em>p<\/em>&nbsp;= 0.008). In the validation cohort, complete VETC-HCC was associated with worse outcomes in patients treated with durvalumab + tremelimumab (PFS: HR 2.44, 95% CI 1.12\u20135.29,&nbsp;<em>p<\/em>&nbsp;= 0.024; OS: HR 3.90, 95% CI 1.66\u20139.15,&nbsp;<em>p<\/em>&nbsp;= 0.002). Patients with complete VETC-HCC and treated with atezolizumab + bevacizumab had longer survival than patients with complete VETC-HCC and treated with durvalumab + tremelimumab (PFS: HR 0.43, 95% CI 0.17\u20131.06,&nbsp;<em>p<\/em>&nbsp;= 0.07; OS: HR 0.19, 95% CI 0.07\u20130.51,&nbsp;<em>p<\/em>&nbsp;= 0.001).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"sectitle0025\">Conclusions<\/h3>\n\n\n\n<p>We identified complete VETC as a potential predictive marker of outcomes in patients with advanced HCC and treated with atezolizumab + bevacizumab or durvalumab + tremelimumab. Prospective validation of these findings is warranted.<\/p>\n\n\n\n<p><\/p>\n","protected":false},"featured_media":82946,"template":"","meta":{"_acf_changed":true},"category_publication":[402,403,404],"class_list":["post-82945","publication","type-publication","status-publish","has-post-thumbnail","hentry","category_publication-publications-mises-en-avant","category_publication-publication-sur-la-banniere","category_publication-publications-marquantes"],"acf":{"numero_de_publication":"JHEP Reports","date_de_publication":"20260611","numero_doi":"10.1016\/j.jhepr.2026.101874","equipe":[335],"auteurs-liste":[{"texte_libre":true,"auteur-lien":null,"auteur-text":"Alexandre Sayadi"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Claudia Campani"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Astrid Laurent-Bellue"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Marianne Ziol"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Luca Di Tommaso"},{"texte_libre":false,"auteur-lien":82926,"auteur-text":""},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Benoit Terris"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Julien Calderaro"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Luca Messerini"},{"texte_libre":false,"auteur-lien":13019,"auteur-text":""},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Federico Lipsich"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Carolina Gutierrez"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Marion Dhooge"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Lisa Lellouche"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Giuliana Amaddeo"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Alina Pascale"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Olivier Rosmorduc"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Fabio Marra"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Lorenza Rimassa"},{"texte_libre":false,"auteur-lien":14728,"auteur-text":""},{"texte_libre":false,"auteur-lien":63210,"auteur-text":""}],"auteurs-manuel":"","liens_externes":[{"url":"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S258955592600145X"}],"liens":null,"paragraphe":"","paragraphe_en":"","documents":null},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab\u2013bevacizumab - CRI<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cri1149.fr\/en\/publication\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab\u2013bevacizumab - CRI\" \/>\n<meta property=\"og:description\" content=\"In this French\u2013Italian cohort, the VETC phenotype was predictive of improved outcomes in patients treated with atezolizumab\u2013bevacizumab, with longer survival than patients treated with durvalumab-tremelimumab. Our findings suggest that VETC represent a promising biomarker for treatment stratification in advanced HCC. Prospective validation studies are now needed to determine whether VETC status could help guide the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cri1149.fr\/en\/publication\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\/\" \/>\n<meta property=\"og:site_name\" content=\"CRI\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cri1149.fr\/wp-content\/uploads\/2026\/06\/1781271821867.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"893\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cri1149.fr\\\/en\\\/publication\\\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\\\/\",\"url\":\"https:\\\/\\\/cri1149.fr\\\/en\\\/publication\\\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\\\/\",\"name\":\"Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab\u2013bevacizumab - CRI\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cri1149.fr\\\/en\\\/publication\\\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cri1149.fr\\\/en\\\/publication\\\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cri1149.fr\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1781271821867.jpg\",\"datePublished\":\"2026-06-24T14:41:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cri1149.fr\\\/en\\\/publication\\\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cri1149.fr\\\/en\\\/publication\\\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cri1149.fr\\\/en\\\/publication\\\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cri1149.fr\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1781271821867.jpg\",\"contentUrl\":\"https:\\\/\\\/cri1149.fr\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1781271821867.jpg\",\"width\":2048,\"height\":893},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cri1149.fr\\\/en\\\/publication\\\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/cri1149.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\\\/\\\/cri1149.fr\\\/publications\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab\u2013bevacizumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#website\",\"url\":\"https:\\\/\\\/cri1149.fr\\\/\",\"name\":\"CRI - Centre de Recherche sur l'Inflammation\",\"description\":\"Centre de Recherche sur l&#039;Inflammation\",\"publisher\":{\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cri1149.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#organization\",\"name\":\"CRI1149\",\"url\":\"https:\\\/\\\/cri1149.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cri1149.fr\\\/wp-content\\\/uploads\\\/2014\\\/11\\\/8.4.2014-logo-CRI.jpg\",\"contentUrl\":\"https:\\\/\\\/cri1149.fr\\\/wp-content\\\/uploads\\\/2014\\\/11\\\/8.4.2014-logo-CRI.jpg\",\"width\":215,\"height\":176,\"caption\":\"CRI1149\"},\"image\":{\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/CRI-Centre-de-recherche-sur-linflammation-100116118884153\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/cri-centre-de-recherche-sur-l-inflammation\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab\u2013bevacizumab - CRI","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cri1149.fr\/en\/publication\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\/","og_locale":"en_US","og_type":"article","og_title":"Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab\u2013bevacizumab - CRI","og_description":"In this French\u2013Italian cohort, the VETC phenotype was predictive of improved outcomes in patients treated with atezolizumab\u2013bevacizumab, with longer survival than patients treated with durvalumab-tremelimumab. Our findings suggest that VETC represent a promising biomarker for treatment stratification in advanced HCC. Prospective validation studies are now needed to determine whether VETC status could help guide the [&hellip;]","og_url":"https:\/\/cri1149.fr\/en\/publication\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\/","og_site_name":"CRI","article_publisher":"https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153","og_image":[{"width":2048,"height":893,"url":"https:\/\/cri1149.fr\/wp-content\/uploads\/2026\/06\/1781271821867.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cri1149.fr\/en\/publication\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\/","url":"https:\/\/cri1149.fr\/en\/publication\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\/","name":"Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab\u2013bevacizumab - CRI","isPartOf":{"@id":"https:\/\/cri1149.fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cri1149.fr\/en\/publication\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\/#primaryimage"},"image":{"@id":"https:\/\/cri1149.fr\/en\/publication\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\/#primaryimage"},"thumbnailUrl":"https:\/\/cri1149.fr\/wp-content\/uploads\/2026\/06\/1781271821867.jpg","datePublished":"2026-06-24T14:41:23+00:00","breadcrumb":{"@id":"https:\/\/cri1149.fr\/en\/publication\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cri1149.fr\/en\/publication\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cri1149.fr\/en\/publication\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\/#primaryimage","url":"https:\/\/cri1149.fr\/wp-content\/uploads\/2026\/06\/1781271821867.jpg","contentUrl":"https:\/\/cri1149.fr\/wp-content\/uploads\/2026\/06\/1781271821867.jpg","width":2048,"height":893},{"@type":"BreadcrumbList","@id":"https:\/\/cri1149.fr\/en\/publication\/vessels-encapsulating-tumor-clusters-predict-better-outcomes-in-advanced-hepatocellular-carcinoma-treated-with-atezolizumab-bevacizumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/cri1149.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https:\/\/cri1149.fr\/publications\/"},{"@type":"ListItem","position":3,"name":"Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab\u2013bevacizumab"}]},{"@type":"WebSite","@id":"https:\/\/cri1149.fr\/#website","url":"https:\/\/cri1149.fr\/","name":"CRI - Centre de Recherche sur l'Inflammation","description":"Centre de Recherche sur l&#039;Inflammation","publisher":{"@id":"https:\/\/cri1149.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cri1149.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cri1149.fr\/#organization","name":"CRI1149","url":"https:\/\/cri1149.fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cri1149.fr\/#\/schema\/logo\/image\/","url":"https:\/\/cri1149.fr\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg","contentUrl":"https:\/\/cri1149.fr\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg","width":215,"height":176,"caption":"CRI1149"},"image":{"@id":"https:\/\/cri1149.fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153","https:\/\/www.linkedin.com\/company\/cri-centre-de-recherche-sur-l-inflammation\/"]}]}},"_links":{"self":[{"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/publication\/82945","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/types\/publication"}],"acf:term":[{"embeddable":true,"taxonomy":"equipes","href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/equipes\/335"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/media\/82946"}],"wp:attachment":[{"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/media?parent=82945"}],"wp:term":[{"taxonomy":"category_publication","embeddable":true,"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/category_publication?post=82945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}